Atanasio
Pandiella Alonso
Fundación Jiménez Díaz
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Fundación Jiménez Díaz (6)
2023
-
Considerations for the clinical development of immuno-oncology agents in cancer
Frontiers in immunology, Vol. 14, pp. 1229575
2022
-
mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
Molecular Cancer Research, Vol. 20, Núm. 7, pp. 1108-1121
2021
-
Preclinical and clinical characterization of fibroblast-derived neuregulin-1 on trastuzumab and pertuzumab activity in HER2-positive breast cancer
Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5096-5108
2019
-
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study
Breast Cancer Research and Treatment, Vol. 174, Núm. 3, pp. 693-701
2017
-
A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study
Oncotarget, Vol. 8, Núm. 42, pp. 73144-73153
-
Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer
Clinical Cancer Research, Vol. 23, Núm. 22, pp. 7006-7019